Giotrif for Advanced Non Small Cell Lung Cancer - Details


( Dernière mise à jour : septembre 2, 2016)
Generic Name:
Afatinib
État du projet:
Terminé
Domaine thérapeutique:
Advanced or Metastatic Non-Small Cell Lung Cancer
Fabricant:
Boehringer Ingelheim Canada Ltd.
Brand Name:
Giotrif
Gamme de produits:
Examen en vue du remboursement
Numéro de projet :
PC0032-000
NOC Date:

Détails


Strength:
20mg, 30mg, and 40mg tablets
Tumour Type:
Lung
Indications:
Advanced Non Small Cell Lung Cancer
Funding Request:
For the first line treatment of EGFR Mutation Positive, Advanced Non-Small Cell Lung Cancer patients
Review Status:
Complete
Pre Noc Submission:
Yes
Date NOC Issued:
Sponsor:
Boehringer Ingelheim Canada Ltd.
Submission Date:
Submission Deemed Complete:
Priorisation demandée:
Non demandée
Stakeholder Input Deadline ‡:
Check-point meeting:
pERC Meeting:
Initial Recommendation Issued:
Feedback Deadline ‡:
Notification to Implement Issued:
Clarification:
A delay in the receipt of Category 2 Part 2 requirements has impacted the review timeline.
Recommandation:
Couvrir le remboursement
Clarification:
A delay in the receipt of Category 2 Part 2 requirements has impacted the review timeline.
Funding Request:
For the first line treatment of EGFR Mutation Positive, Advanced Non-Small Cell Lung Cancer patients
pERC Meeting:
Final Recommendation Issued:

Fichiers

‡ Patient Advocacy Groups (or individual patients and caregivers when there is no patient group) and Clinicians who are registered with pCODR are eligible to provide Input and Feedback. Deadlines for Input and Feedback are by the end of the pCODR business day (5P.M. Eastern Time) of the date noted.